1. People's Republic of China Stocks

  2. •

    Healthcare

  3. •

    Drug Manufacturers - Specialty & Generic
Baotou Dongbao Bio-Tech Co.,Ltd

Baotou Dongbao Bio-Tech Co.,Ltd

300239.SZ
Baotou Dongbao Bio-Tech Co.,LtdCN flagShenzhen Stock Exchange
4.92
CNY
-0.08
- -
2.92BMarket Cap
Baotou Dongbao Bio-Tech Co.,Ltd
300239.SZ
(Shenzhen Stock Exchange)

Recent

price

4.92

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
0.65
0.6
0.65
0.97
0.63
0.72
0.69
0.77
0.98
0.97
0.86
1.09
1.59
1.64
1.49
1.27
1.37
Revenue per Share
0.07
0.07
0.09
0.11
0.01
0.01
0.04
0.05
0.07
0.06
0.04
0.06
0.18
0.2
0.14
0.09
0.12
Basic EPS, GAAP
0.01
-0.08
-0.12
-0.04
-0.07
-0.1
-0.25
-0.23
0.01
-0.34
-0.17
- -
0.15
0.11
-0.01
0.05
-0.12
Free Cash Flow per Basic Share
0.02
0.02
0.01
0.04
0.04
0.04
0.01
0.02
0.03
0.04
0.04
0.01
0.02
0.04
0.03
0.03
0.03
Dividend per Share
0.34
0.41
0.61
0.71
0.68
0.74
1.18
1.2
1.24
1.27
1.23
1.33
1.42
1.58
1.69
1.78
1.74
Book Value per Share
0.39
0.83
0.8
0.86
0.82
1.56
1.4
1.42
1.48
1.82
1.75
2.52
2.7
2.94
2.69
2.71
2.66
Tangible Book Value per Share
296
346
395
395
396
406
461
461
461
507
523
564
593
593
594
586
590
Basic Weighted Avg Shares
192
208
256
382
251
292
317
356
453
492
449
612
943
975
885
745
810
Sales/Revenue/Turnover
15.28
13.67
17.81
14.06
4.42
4.11
4.55
7.99
9.69
7.52
5.97
7.33
14.42
15.38
12.16
10.72
11.2
Operating Margin (%)
7
8
10
13
15
16
18
27
36
35
49
55
86
82
86
97
- -
Depreciation Expense
22
25
35
43
5
6
19
22
34
33
18
36
109
120
86
54
72
Net Income, GAAP
15.52
15.17
15.44
16.75
24.7
20.26
15.65
15.2
13.26
9.87
7.47
13.76
12.31
11.85
13.6
12.25
13.72
Effective Tax Rate (%)
11.24
11.89
13.84
11.16
1.95
2.02
6.07
6.29
7.5
6.69
4.11
5.96
11.6
12.3
9.72
7.29
8.84
Profit Margin (%)
15
142
229
250
133
420
243
121
116
228
133
471
708
1,049
911
913
916
Working Capital
10
10
107
108
10
10
10
24
16
27
8
- -
152
463
472
494
509
LT Debt
122
296
324
351
341
707
719
730
751
990
998
1,604
1,756
1,893
1,739
1,723
1,706
Total Equity
14.04
8.96
9.86
10.07
1.83
1.64
1.69
3.27
4.84
3.56
2.29
2.79
6.6
6.12
4.06
3.16
3.38
Return on Invested Capital (%)
16.36
15.19
14.64
13.79
3.2
3.55
4.44
3.99
5.99
5.06
3.25
4.71
9.79
8.04
5.3
3.82
4.54
Return on Capital (%)
23.64
20.26
18.38
16.31
1.78
2.06
4.55
4.09
6.05
5.41
2.86
5.23
13.72
13.44
8.85
5.31
7.15
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Dec'24
Mar'25
Jun'25
ST Debt
8
8
10
LT Borrowings
472
516
509
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
594
594
594
Market Capitalization
3,719
3,090
3,496

Working Capital

FRC

•

in mil. unless spec.
Dec'24
Mar'25
Jun'25
Total Current Assets
1,235
1,210
1,188
Cash, Cash Equivalents & STI
532
478
521
Accounts Receivable, Net
206
213
191
Inventories
354
372
394
Total Current Liabilities
324
269
272
Payables & Accruals
- -
- -
- -
ST Debt
8
8
10
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
10.77%
13.78%
-0.93%
Free Cash Flow
5,342%
11,417.07%
-431.67%
Net Income, GAAP
48.97%
48.43%
-36.8%
Sales/Revenue/Turnover
11.68%
13.77%
-15.78%
Total Cash Common Dividend
23.68%
20.64%
15.62%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
242
202
189
252
885
2025
188
181
213
- -
745
2026
191
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.04
- -
- -
- -
0.14
2025
0.03
- -
- -
- -
0.09
2026
0.03
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
0.03
2025
- -
- -
- -
- -
0.03
2026
- -
- -
- -
- -
- -
Similar Companies
PLx Pharma Inc. (PLXP)
BIGtoken, Inc. (FPVD)
Perrigo Company plc (PRGO)
Jubilant Pharmova Limited (JUBLPHARMA.BO)
Maple Leaf Green World Inc. (MGW.CN)
Columbia Care Inc. (CCHW.CN)
Business
Baotou Dongbao Bio-Tech Co., Ltd. Baotou Dongbao Bio-Tech Co., Ltd. (300239.SZ), founded in 1997 as the successor to Baotou Fine Gelatin Factory established in the 1960s, develops, manufactures and sells gelatin, collagen and related derivative products from its headquarters in Baotou, Inner Mongolia, China. The company operates three production bases with annual capacities of 13,500 metric tons for gelatin and 4,300 metric tons for collagen peptides; its core offerings include pharmaceutical gelatin for empty hard capsules, softgels and plasma substitutes; food additive gelatin serving as thickener, stabilizer, emulsifier in confectionery, dairy, meat and yogurt products; photographic gelatin; hydrolyzed collagen powder and granules; collagen peptide powder, granules and agglomerated forms; fish collagen peptide; private label collagen OEM/ODM services; feed-grade calcium hydrogen phosphate; and bio-organic fertilizers such as organic, water-soluble and compound microbial variants. Products target pharmaceutical, food and nutraceutical, industrial, fertilizer and animal feed sectors primarily in China with international exports, holding top production rankings and high market share in China's softgel and hard capsule segments. In 2024, Baotou Dongbao Bio-Tech Co., Ltd. completed its acquisition of the remaining 40% stake in Qingdao Yiqing Biotechnology Co., Ltd. for CNY 230 million, achieving 100% ownership to bolster collagen production capabilities.